BioPharmSignal logoBioPharmSignal

Biotech News

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

Aligos Therapeutics (ALGS)Aligos TherapeuticsConference / presentation

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted

Related news

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

MLYSMineralys Therapeutics2026-06-08 11:00 EST

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

RYTMRhythm Pharmaceuticals2026-05-29 12:00 EST

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

MLYSMineralys Therapeutics2026-10-02 20:30 EST

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

ALTAltimmune2026-09-03 12:00 EST

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

SGMTSagimet Biosciences2026-08-04 11:00 EST

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

View all latest news

Aligos Therapeutics

Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B...

Recent company news

ALGSAligos Therapeutics2026-10-05 20:05 EST

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

ALGSAligos Therapeutics2026-08-12 20:05 EST

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

ALGSAligos Therapeutics2026-08-12 20:05 EST

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Stock data

Close
5.50 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States